evaluate the pharmaceutical company trulicity on glp 1 A new study from NYU Langone finds that GLP-1 agonists—medications like Ozempic, Wegovy, and Trulicity—may offer unexpected benefits for kidney transplant recipients with type 2 diabetes. , Trulicity is now available #EVAPharma

IQVIA LAAD Rx for the period of June 2021 to July 2024

Challenges, Side Effects, and Cost Gastrointestinal symptoms like nausea and diarrhea are common with GLP1 therapies, including oral versions

generated a novel family of non-covalent, benzimidazole-based DPP-4 inhibitors from a small fragment hit (110)

Retatrutide: Surgery-Level Results from a Triple Agonist The most striking data to emerge from the GLP-1 drug pipeline in 2026 comes from retatrutide, Eli Lillys investigational first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

Konturek PC, Konturek JW, Czesnikiewicz-Guzik M, Brzozowski T, Sito E, Konturek SJ

Nat Rev Endocrinol (2018) 14(10):591604